Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response

Immunology Letters

Volumn 57, Issue 1-3, 1997, Pages 19-25

  Christ, Marielle ^a   Lusky, Monika ^a   Stoeckel, Fabienne ^a   Dreyer, Dominique ^a   Dieterle, Annick ^a   Michou, Anne Isabelle ^a   Pavirani, Andrea ^a   Mehtali, Majid ^a  

^a TRANSGENE S A   (France)

Author keywords

Adenovirus; Gene therapy; Immune response

Indexed keywords

CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ADENOVIRUS; CELLULAR IMMUNITY; CONFERENCE PAPER; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; TRANSGENE; VIRUS GENE; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANIMALS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

EID: 0030756821     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(97)00049-7     Document Type: Conference Paper

References (36)

1. J.L. Imler, A. Bout, D. Dreyer, A. Dieterlé, H. Schultz, D. Valério, M. Mehtali, A. Pavirani, Trans-complementation of El-deleted adenovirus: a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses, Hum. Gene Ther. 6 (1995) 711-721.
2. F.L. Graham, J. Smiley, W.C. Russell, R. Nairn, Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen. Virol. 36 (1977) 59-72.
3. P.B. Arbuthnot, M.P. Bralet, C. Le Jossic, J.F. Dedieu, M. Perricaudet, C. Bréchot, N. Ferry, in vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector, Hum. Gene Ther. 7 (1996) 1503-1514.
4. J.F. Engelhardt, L. Litzky, J.M. Wilson, Prolonged transgene expression in Cotton rat lung with recombinant adenoviruses in E2a, Hum. Gene Ther. 5 (1994) 1217-1229.
5. G. Acsadi, A. Jani, J. Huard, K. Blaschuk, B. Massie, P. Holland, H. Lochmuller, G. Karpati, Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther. 1 (1994) 338-340.
6. G. Acsadi, H. Lochmuller, A. Jani, J. Huard, B. Massie, S. Prescott, M. Simoneau, B.J. Pretof, G. Karpati, Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer, Hum. Gene Ther. 7 (1996) 129-140.
7. B. Quantin, L.D. Perricaudet, S. Tajbakhsh, J.L. Mandel, Adenovirus as an expression vector in muscle cells in vivo, Proc. Natl. Acad. Sci. USA 89 (1992) 2581-2584.
8. A. Bout, J.L. Imler, H. Schultz, M. Perricaudet, C. Zurcher, P. Herbrink, D. Valerio, A. Pavirani, In vivo adenovirus-mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium: efficacy, toxicity and safety, Gene Ther. 1 (1994) 385-394.
9. G. Bellon, et al., Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial, Hum. Gene Ther. 8 (1997) 15-25.
10. S.E. Haecker, H.H. Stedman, R.J. Balice-Gordon, D.B.J. Smith, J.P. Greelish, M.A. Mitchell, A. Wells, H.L. Sweeney, J.M. Wilson, in vivo expression of full length human dystophin from adenoviral vectors deleted of all viral genes, Hum. Gene Ther. 7 (1996) 1907-1914.
11. T. Ragot, N. Vincent, P. Chafey, E. Vigne, H. Gilgenkrantz, D. Couton, J. Cartaud, P. Briand, M. Perricaudet, A. Kahn, Efficient adenovirus-mediated gene transfer of a human minidystrophin gene to skeletal muscle of mdx mice, Nature 361 (1993) 647-650.
12. A.I. Michou, M. Christ, M. Mehtali, Thérapie génique des hémophilies. Potentialités thérapeutiques et limitations technologiques. Transfusion Clin. Biol. 4 (1997a) 251-261.
13. S.N. Yao, A. Farjo, B.J. Roessler, B. Davidson, K. Kurachi, Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver. Viral Immunol. 9 (1996) 141-153.
14. A.I. Michou, L. Santoro, M. Christ, V. Julliard, A. Pavirani, M. Mehtali, Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression, Gene Ther. 4 (1997b) 473-482.
15. Y. Yang, Q. Il, H.C.J. Ertl, J.M. Wilson, Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol. 69 (1995) 2004-2015.
16. Y. Yang, Q. Su, I.S. Grewal, R. Schilz, R.A. Flavell, J.M. Wilson, Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues, J. Virol. 70 (1996) 6370-6377.
17. Y. Yang, S.E. Haecker, J.M. Wilson, Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle, Hum. Mol. Genet. 5 (1996) 1703-1712.
18. Y. Yang, K.U. Jooss, Q. Su, H.C.J. Ertl, J. Wilson, Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3 (1996) 137-144.
19. Y. Yang, Q. Su, J.M. Wilson, Role of viral antigens in destruc-live cellular immune responses to adenovirus vector-transduced cells in mouse lungs, J. Virol. 70 (1996) 7209-7212.
20. V. Juillard, P. Villefroy, D. Godfrin, A. Pavirani, A. Venet, J.G. Guillet, Long term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector, Eur. J. Immunol. 25 (1995) 3467-3473.
21. S.K. Tripathy, H.B. Black, E. Goldwasser, J. Leiden, Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2 (1996) 545-550.
22. J.M. Kaplan, D. Armentano, T.E. Sparer, S.G. Wynn, P.A. Peterson, S.C. Wadsworth, K.K. Couture, S.E. Pennington, J.A. St George, L.R. Gooding, A.E. Smith, Characterization of factors involved in modulating pesistence of transgene expression from recombinant adenovirus in the mouse lung, Hum. Gene Ther. 8 (1997) 45-56.
23. B. Fang, H. Wang, G. Gordon, D.A. Bellinger, M.S. Read, K.M. Brinklaus, S.L.C. Woo, R.C. Eisensmith, Lack of persistence of El-recombinant adenoviral vectors containing a temperature sensitive E2a mutation in immunocompetent mice and hemophilia B dogs, Gene Ther. 3 (1996) 217-222.
24. G.P. Gao, Y. Yang, J.M. Wilson, Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy, J. Virol. 70 (1996) 8934-8943.
25. S. Worgall, G. Wolff, E. Falck-Pedersen, R.G. Crystal, Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration, Hum. Gene Ther. 8 (1997) 37-44.
26. G. Wolff, S. Worgall, N. Van Rooijen, W.R. Song, B.C. Harvey, R. Crystal, Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ, J. Virol. 71 (1997) 624-629.
27. K. Jooss, Y. Yang, J.M. Wilson, Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung, Hum. Gene Ther. 7 (1996) 1555-1566.
28. H. Lochmüller, B.J. Petrof, G. Pari, N. Larochelle, V. Dodelet, Q. Wang, C. Allen, S. Prescott, B. Massie, J. Nalbantoglu, G. Karpati, Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice, Gene Ther. 3 (1996) 706-716.
29. R.P. De Matteo, J.F. Markmann, K.F. Kozarsky, C.F. Barker, S.E. Raper, Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion, Gene Ther. 3 (1996) 4-12.
30. J.K. Kolls, D. Lei, G. Odom, S. Nelson, W. Summer, M.A. Gerber, J.E. Shellito, Use of transient CD4 lymphocyte depletion to prolong transgene expression of El-deleted adenoviral vectors, Hum. Gene Ther. 7 (1996) 489-497.
31. S.J. Sawchuk, G.P. Boivin, L.E. Duwel, W. Ball, K. Bove, B. Trapnell, R. Hirsch, Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium, Hum. Gene Ther. 7 (1996) 499-506.
32. B. Guérette, J.T. Vilquin, M. Gingras, C. Gravel, K.J. Wood, J.P. Tremblay, Prevention of immune reactions by first generation adenoviral vectors by monoclonal antibodies and CTLA4Ig, Hum. Gene Ther. 7 (1996) 1455-1463.
33. M.A. Kay, A.X. Holterman, L. Mense, A. Gown, H.D. Ochs, P.S. Linsley, C.B. Wilson, Long term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration, Nature Genet. 11 (1995) 191-197.
34. Y. Ilan, G. Droguett, N.R. Chowdhury, Y. Il, K. Sengupta, N. Thummala, A. Davidson, J.R. Chowdhury, M.S. Horwitz, Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression, Proc. Natl. Acad. Sci. USA 94 (1997) 2587-2592.
35. Y. Yang, J.M. Wilson, CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40, Science 273 (1996) 1862-1864.
36. S. Connelly, J.M. Gardner, R.M. Lyons, A. McClelland, M. Kaleko, Sustained expression of therapeutic levels of human factor VIII in mice, Blood 87 (1996) 4671-4677.